Conference Proceedings

Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from > 4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study

JS de Bono, K Fizazi, F Saad, N Shore, SK Sandhu, N Mehra, M Kolinsky, G Roubaud, M Ozguroglu, N Matsubara, C Gedye, YD Choi, C Padua, C Goessl, A Kohlmann, C Corcoran, CA Adelman, A Allen, J Burgents, M Hussain

ANNALS OF ONCOLOGY | OXFORD UNIV PRESS | Published : 2019

Grants

Funding Acknowledgements

AstraZeneca and Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc, Kenilworth, NJ, USA.